Physiological Barriers, System Design, and Applications in Disease Prevention and Treatment for Local mRNA Delivery to the Respiratory Tract

ABSTRACT Messenger RNA (mRNA) therapies enable transient, controllable, and programmable protein expression without integrating into the host genome. However, pulmonary mRNA delivery remains constrained by airway deposition, mucociliary clearance, mucus entrapment, pulmonary surfactant interactions, extracellular nuclease degradation, nonspecific immune‐cell uptake, and inefficient endosomal escape. This review systematically examines local pulmonary mRNA delivery through a three‐tier barrier framework encompassing airway clearance, the alveolar microenvironment, and intracellular trafficking, and further discusses how disease‐specific pathological microenvironments remodel these barriers. We compare major non‐viral delivery platforms, including lipid nanoparticles, polymeric nanoparticles, liposomes, micelles, and extracellular vesicles, with emphasis on their molecular design, physicochemical properties, nebulization stability, mucus penetration, intracellular release, and translational limitations. Representative applications in protein replacement, mucosal vaccination, lung cancer immunotherapy, and inflammatory and fibrotic lung diseases are also summarized. Particular emphasis is placed on three interconnected dimensions: maintaining formulation stability during nebulization, adapting delivery systems to disease‐remodeled pulmonary barriers, and achieving cell‐selective mRNA delivery. Finally, we discuss pulmonary safety, repeated administration, disease‐relevant functional outcomes, and preclinical‐to‐clinical translation. By integrating barriers, carrier design, therapeutic applications, and translational considerations, this review provides a framework for the rational development of safe, reproducible, and clinically meaningful pulmonary mRNA therapies.

Authors

Institutions

Publication Details

Journal
MedComm – Biomaterials and Applications
Published
2026-11-16
DOI
https://doi.org/10.1002/mba2.70083
Primary Topic
RNA Interference and Gene Delivery
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Physiological Barriers, System Design, and Applications in Disease Prevention and Treatment for Local mRNA Delivery to the Respiratory Tract

Longwei Xiang, Kai Hao, Huayu Tian, Yunni You
MedComm – Biomaterials and Applications
RNA Interference and Gene Delivery
article

Physiological Barriers, System Design, and Applications in Disease Prevention and Treatment for Local mRNA Delivery to the Respiratory Tract

Longwei Xiang, Kai Hao, Huayu Tian, Yunni You
article en

Abstract

ABSTRACT Messenger RNA (mRNA) therapies enable transient, controllable, and programmable protein expression without integrating into the host genome. However, pulmonary mRNA delivery remains constrained by airway deposition, mucociliary clearance, mucus entrapment, pulmonary surfactant interactions, extracellular nuclease degradation, nonspecific immune‐cell uptake, and inefficient endosomal escape. This review systematically examines local pulmonary mRNA delivery through a three‐tier barrier framework encompassing airway clearance, the alveolar microenvironment, and intracellular trafficking, and further discusses how disease‐specific pathological microenvironments remodel these barriers. We compare major non‐viral delivery platforms, including lipid nanoparticles, polymeric nanoparticles, liposomes, micelles, and extracellular vesicles, with emphasis on their molecular design, physicochemical properties, nebulization stability, mucus penetration, intracellular release, and translational limitations. Representative applications in protein replacement, mucosal vaccination, lung cancer immunotherapy, and inflammatory and fibrotic lung diseases are also summarized. Particular emphasis is placed on three interconnected dimensions: maintaining formulation stability during nebulization, adapting delivery systems to disease‐remodeled pulmonary barriers, and achieving cell‐selective mRNA delivery. Finally, we discuss pulmonary safety, repeated administration, disease‐relevant functional outcomes, and preclinical‐to‐clinical translation. By integrating barriers, carrier design, therapeutic applications, and translational considerations, this review provides a framework for the rational development of safe, reproducible, and clinically meaningful pulmonary mRNA therapies.

MedComm – Biomaterials and ApplicationsVol. 5(4)
University of Science and Technology of China (CN), Xiamen University (CN), Chinese Academy of Sciences (CN), Changchun Institute of Applied Chemistry (CN)
RNA Interference and Gene Delivery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon